An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in <i>RB1</i>

Lisa‐Maj Christensen(Aalborg University Hospital), Daniel Tuyet Kristensen(Aalborg University Hospital), Marianne Tang Severinsen(Aalborg University Hospital), Paw Jensen(Aalborg University Hospital), Thor Høyer(Aalborg University Hospital), Andreas Kiesbye Øvlisen(Aalborg University Hospital), Pragya Katoch(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital)

Journal of Hematology

June 1, 2023

10.14740/jh1132

Cited by 3

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247